Todd Busman

5.1k total citations · 2 hit papers
42 papers, 2.6k citations indexed

About

Todd Busman is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Todd Busman has authored 42 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Todd Busman's work include Chronic Lymphocytic Leukemia Research (21 papers), Pneumonia and Respiratory Infections (10 papers) and Advanced Breast Cancer Therapies (7 papers). Todd Busman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Pneumonia and Respiratory Infections (10 papers) and Advanced Breast Cancer Therapies (7 papers). Todd Busman collaborates with scholars based in United States, Australia and United Kingdom. Todd Busman's co-authors include Rod Humerickhouse, Sari H. Enschede, Hao Xiong, Andrew Krivoshik, Yue Cui, Yi‐Lin Chiu, Evelyn McKeegan, William G. Wierda, Andrew W. Roberts and John F. Seymour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Todd Busman

42 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

2011 632 citations Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd Busman United States	20	1.5k	681	655	514	459	42	2.6k
Kylie D. Mason Australia	18	2.4k 1.7×	588 0.9×	809 1.2×	505 1.0×	908 2.0×	58	4.0k
Heinz Sill Austria	32	1.2k 0.8×	568 0.8×	912 1.4×	438 0.9×	1.2k 2.6×	137	3.3k
Eleftheria Hatzimichael Greece	30	1.6k 1.1×	565 0.8×	554 0.8×	285 0.6×	677 1.5×	114	3.0k
Virginie Penard‐Lacronique France	23	1.4k 1.0×	592 0.9×	829 1.3×	235 0.5×	977 2.1×	44	2.8k
Soo‐Yong Tan Singapore	27	1.2k 0.9×	301 0.4×	686 1.0×	617 1.2×	162 0.4×	106	2.6k
Alexander Egle Austria	35	2.0k 1.3×	1.2k 1.8×	1.5k 2.2×	903 1.8×	586 1.3×	153	4.2k
Ayad Al‐Katib United States	33	1.6k 1.1×	1.2k 1.7×	1.1k 1.7×	1.1k 2.1×	499 1.1×	123	3.7k
Ronan Swords United States	27	1.8k 1.3×	464 0.7×	655 1.0×	289 0.6×	1.1k 2.4×	115	3.0k
Rose Ann Padua United Kingdom	32	1.6k 1.1×	464 0.7×	926 1.4×	208 0.4×	1.2k 2.6×	104	3.1k
Valérie Gouilleux‐Gruart France	28	1.0k 0.7×	416 0.6×	1.4k 2.1×	338 0.7×	556 1.2×	82	3.0k

Countries citing papers authored by Todd Busman

Since Specialization

Citations

This map shows the geographic impact of Todd Busman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Busman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Busman more than expected).

Fields of papers citing papers by Todd Busman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Busman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Busman. The network helps show where Todd Busman may publish in the future.

Co-authorship network of co-authors of Todd Busman

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Busman. A scholar is included among the top collaborators of Todd Busman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Busman. Todd Busman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davids, Matthew S., Michael Hallek, William G. Wierda, et al.. (2018). Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 24(18). 4371–4379. 113 indexed citations

Wierda, William G., John F. Seymour, Andrew W. Roberts, et al.. (2017). Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 130. 4329–4329. 2 indexed citations

Tolcher, Anthony W., Patricia LoRusso, Jennifer A. Arzt, et al.. (2015). Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemotherapy and Pharmacology. 76(5). 1041–1049. 26 indexed citations

Tolcher, Anthony W., Patricia LoRusso, Jennifer A. Arzt, et al.. (2015). Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 76(5). 1025–1032. 50 indexed citations

Cleary, James M., Caio Max S. Rocha Lima, Herbert I. Hurwitz, et al.. (2014). A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investigational New Drugs. 32(5). 937–945. 59 indexed citations

Konopleva, Marina, Daniel A. Pollyea, Jalaja Potluri, et al.. (2014). A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). Blood. 124(21). 118–118. 50 indexed citations

Vlahovic, Gordana, Vassiliki Karantza, Ding Wang, et al.. (2014). A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Investigational New Drugs. 32(5). 976–984. 46 indexed citations

Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7018–7018. 20 indexed citations

Seymour, John F., Matthew S. Davids, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. Blood. 120(21). 3923–3923. 6 indexed citations

10.

Davids, Matthew S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood. 120(21). 304–304. 28 indexed citations

11.

Gandhi, Leena, D. Ross Camidge, Moacyr Oliveira, et al.. (2011). Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology. 29(7). 909–916. 462 indexed citations

12.

Wilson, Wyndham H., Owen A. O’Connor, Myron S. Czuczman, et al.. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet Oncology. 11(12). 1149–1159. 663 indexed citations breakdown →

13.

Gotfried, Mark H., et al.. (2005). Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Current Medical Research and Opinion. 21(2). 245–254. 20 indexed citations

14.

Block, Stan L., Todd Busman, Maria Paris, & Stanley Bukofzer. (2004). Comparison of Five-Day Cefdinir Treatment with Ten-Day Low Dose Amoxicillin/Clavulanate Treatment for Acute Otitis Media. The Pediatric Infectious Disease Journal. 23(9). 834–838. 18 indexed citations

15.

Riffer, Ernie, et al.. (2004). Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Current Medical Research and Opinion. 21(1). 61–70. 13 indexed citations

16.

Busman, Todd, et al.. (2003). Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Current Medical Research and Opinion. 19(5). 411–420. 15 indexed citations

17.

Bonvehí, Pablo, et al.. (2003). Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in???an Era of Drug-Resistant Streptococcus pneumoniae. Clinical Drug Investigation. 23(8). 491–501. 12 indexed citations

18.

Busman, Todd, et al.. (2003). Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Current Medical Research and Opinion. 19(5). 421–429. 13 indexed citations

19.

Gotfried, Mark H., et al.. (2002). A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clinical Therapeutics. 24(5). 736–751. 43 indexed citations

20.

Sokol, William N., et al.. (2002). A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clinical Therapeutics. 24(4). 605–615. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact